Search Results

A ‘rule book’ to guide precision combination immunotherapies and speed up the development of new lung cancer treatments will be created as part of a new collaboration between the Crick, Cancer Research UK and Bristol Myers-Squibb.

Using a combination of drugs and diet to block the many different ways tumours create energy and building blocks could offer potentially effective new cancer treatments, according to new research in mice and cells from the Crick

A key mechanism controlling tissue structure, which could help identify drugs that make it harder for cancer cells to spread, has been identified by researchers at the Francis Crick Institute.

Researchers at the Crick have developed a method that could help predict whether people with lung cancer will respond to chemotherapy, based on which genes are switched on in their tumour. 

Researchers from the Crick, King’s College London and UCL have found that high levels of a unique type of immune cell are linked to a greater chance of remaining cancer-free after surgery for patients with lung cancer. 

Researchers at the Crick , The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumours that can help predict if patients with kidney cancer will respond to immunotherapy. 

Remnants of ancient retroviruses passed down in our DNA could be an effective target for antibodies against lung cancer, according to new findings from researchers at the Francis Crick Institute.

Researchers at the Crick and Universidade de Santiago de Compostela have identified how the hepatitis B virus can support the survival and growth of liver cancer, with this process starting early in tumour development

Crick group leaders Guillaume Salbreux and Axel Behrens, along with Chris Dunsby from Imperial College London, have been awarded a £2m grant from the Engineering and Physical Sciences Research Council (EPSRC).

Achilles Therapeutics, a company built on the research of Crick group leader Charles Swanton and Sergio Quezada and Karl Peggs at the UCL Cancer Institute, has started a clinical trial for a new personalised immunotherapy for patients with melanoma.